Sofiva Genomics Co., Ltd.(TW:6615)
NT$32.50+0.25 (+0.78%)
TW:6615
Sofiva Genomics Co., Ltd. financials statements
NT$32.50
At close:+0.25 (+0.78%)
Sofiva Genomics Co., Ltd. (6615) Ratios
Sofiva Genomics Co., Ltd. Ratios
TW:6615's free cash flow for Q2 2026 was NT$8.19M. For the 2026 fiscal year, TW:6615's free cash flow was decreased by NT$-1.39M and operating cash flow was NT$9.57M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.33 | 3.27 | 2.88 | 2.79 | 3.03 |
| Quick Ratio | 2.84 | 2.71 | 2.45 | 2.30 | 2.69 |
| Cash Ratio | 1.28 | 1.34 | 1.01 | 1.03 | 1.74 |
| Solvency Ratio | 0.34 | 0.49 | 0.36 | 0.47 | 0.50 |
| Operating Cash Flow Ratio | 0.22 | 0.42 | 0.25 | 0.15 | 0.65 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 19.05 |
| Net Current Asset Value | NT$ 140.28M | NT$ 148.92M | NT$ 128.57M | NT$ 143.64M | NT$ 175.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.07 | 0.08 | 0.09 | 0.11 |
| Debt-to-Equity Ratio | 0.06 | 0.08 | 0.10 | 0.12 | 0.14 |
| Debt-to-Capital Ratio | 0.05 | 0.08 | 0.09 | 0.11 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | 1.19 | 1.24 | 1.29 | 1.32 |
| Debt Service Coverage Ratio | 8.64 | 55.68 | 23.98 | 28.46 | 11.82 |
| Interest Coverage Ratio | -39.83 | -3.04 | -12.33 | 32.47 | 37.55 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.67 | 2.54 | 3.04 | 3.57 | 4.32 |
| Net Debt to EBITDA | -7.00 | -0.88 | -1.19 | -0.97 | -1.62 |
| Profitability Margins | |||||
| Gross Profit Margin | 25.70% | 29.93% | 27.83% | 30.05% | 34.78% |
| EBIT Margin | -8.75% | 5.45% | -2.89% | 0.76% | 6.93% |
| EBITDA Margin | 2.04% | 14.64% | 5.97% | 9.39% | 15.18% |
| Operating Profit Margin | -8.75% | -0.74% | -3.40% | 9.75% | 12.84% |
| Pretax Profit Margin | -2.15% | 5.21% | 1.91% | 9.55% | 12.53% |
| Net Profit Margin | -2.43% | 4.07% | 2.47% | 8.63% | 11.21% |
| Continuous Operations Profit Margin | -2.30% | 4.22% | 2.55% | 0.25% | 5.06% |
| Net Income Per EBT | 112.72% | 78.04% | 129.47% | 90.34% | 89.45% |
| EBT Per EBIT | 24.61% | -700.12% | -56.06% | 97.93% | 97.55% |
| Return on Assets (ROA) | -1.29% | 2.40% | 1.50% | 5.30% | 6.93% |
| Return on Equity (ROE) | -1.49% | 2.86% | 1.86% | 6.82% | 9.13% |
| Return on Capital Employed (ROCE) | -5.16% | -0.49% | -2.37% | 6.99% | 9.34% |
| Return on Invested Capital (ROIC) | -5.06% | -0.39% | -2.32% | 6.24% | 8.11% |
| Return on Tangible Assets | -1.30% | 2.43% | 1.52% | 5.34% | 6.98% |
| Earnings Yield | -1.43% | 2.15% | 1.31% | 5.46% | 5.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.21 | 6.87 | 6.15 | 6.00 | 6.45 |
| Payables Turnover | 12.66 | 14.14 | 10.62 | 6.85 | 5.67 |
| Inventory Turnover | 8.22 | 6.85 | 8.06 | 6.08 | 7.98 |
| Fixed Asset Turnover | 5.60 | 4.39 | 4.02 | 3.84 | 3.95 |
| Asset Turnover | 0.53 | 0.59 | 0.61 | 0.61 | 0.62 |
| Working Capital Turnover Ratio | 2.18 | 2.45 | 2.40 | 2.16 | 2.10 |
| Cash Conversion Cycle | 74.30 | 80.58 | 70.29 | 67.69 | 37.99 |
| Days of Sales Outstanding | 58.74 | 53.09 | 59.38 | 60.87 | 56.57 |
| Days of Inventory Outstanding | 44.39 | 53.31 | 45.27 | 60.08 | 45.75 |
| Days of Payables Outstanding | 28.83 | 25.82 | 34.36 | 53.26 | 64.33 |
| Operating Cycle | 103.13 | 106.41 | 104.66 | 120.95 | 102.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.71 | 1.61 | 1.11 | 0.80 | 3.76 |
| Free Cash Flow Per Share | 0.33 | 0.49 | -0.04 | -0.87 | 3.17 |
| Dividend Paid and CapEx Coverage Ratio | 1.05 | 1.22 | 0.52 | 0.22 | 1.89 |
| Capital Expenditure Coverage Ratio | 1.88 | 1.44 | 0.97 | 0.48 | 6.33 |
| Operating Cash Flow Coverage Ratio | 0.43 | 0.65 | 0.37 | 0.23 | 0.89 |
| Operating Cash Flow to Sales Ratio | 0.04 | 0.08 | 0.05 | 0.03 | 0.16 |
| Free Cash Flow Yield | 1.10% | 1.23% | -0.10% | -2.37% | 6.46% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -70.12 | 46.45 | 76.39 | 18.35 | 18.28 |
| Price-to-Sales (P/S) Ratio | 1.70 | 1.89 | 1.89 | 1.58 | 2.05 |
| Price-to-Book (P/B) Ratio | 1.04 | 1.33 | 1.42 | 1.25 | 1.67 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 91.11 | 81.19 | -1025.07 | -42.24 | 15.47 |
| Price-to-Operating Cash Flow Ratio | 42.74 | 24.74 | 37.16 | 45.75 | 13.02 |
| Price-to-Earnings Growth (PEG) Ratio | 0.47 | 0.78 | -1.05 | -0.72 | 0.28 |
| Enterprise Value Multiple | 76.42 | 12.05 | 30.41 | 15.86 | 11.89 |
| Enterprise Value | 601.20M | 799.47M | 847.31M | 738.84M | 917.97M |
| EV to EBITDA | 76.42 | 12.05 | 30.41 | 15.86 | 11.89 |
| EV to Sales | 1.56 | 1.76 | 1.82 | 1.49 | 1.81 |
| EV to Free Cash Flow | 83.46 | 75.64 | -986.40 | -39.80 | 13.62 |
| EV to Operating Cash Flow | 39.15 | 23.05 | 35.75 | 43.12 | 11.46 |
| Tangible Book Value Per Share | 28.63 | 29.62 | 28.65 | 29.06 | 29.05 |
| Shareholders’ Equity Per Share | 28.86 | 29.98 | 28.96 | 29.35 | 29.33 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.07 | 0.19 | -0.34 | 0.09 | 0.11 |
| Revenue Per Share | 17.72 | 21.10 | 21.87 | 23.21 | 23.89 |
| Net Income Per Share | -0.43 | 0.86 | 0.54 | 2.00 | 2.68 |
| Tax Burden | 1.13 | 0.78 | 1.29 | 0.90 | 0.89 |
| Interest Burden | 0.25 | 0.96 | -0.66 | 12.50 | 1.81 |
| Research & Development to Revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 |
| SG&A to Revenue | 0.32 | 0.28 | 0.29 | 0.27 | 0.26 |
| Stock-Based Compensation to Revenue | -0.00 | -0.00 | 0.00 | 0.01 | 0.01 |
| Income Quality | -1.85 | 1.47 | 2.66 | 0.36 | 1.26 |
Currency in TWD
